Tokyo, Japan

Kiyohiro Samizu



 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Tsukuba, JP (2007)
  • Chuo-ku, JP (2014)
  • Tokyo, JP (2012 - 2016)

Company Filing History:


Years Active: 2007-2016

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Kiyohiro Samizu: Innovator in Pharmaceutical Chemistry

Introduction

Kiyohiro Samizu is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target critical health conditions.

Latest Patents

Samizu holds five patents, with his latest inventions focusing on chromane compounds. One of his notable patents describes a hydrate of N-[(4S)-2-amino-2',2′-dimethyldispiro[1,3-oxazole-4,4′-chromene-3′,3″-oxetan]-6′-yl]-5-chloropyridine-2-carboxamide. This compound is useful as an active ingredient in pharmaceutical compositions aimed at preventing or treating diseases associated with β-secretase activity, including Alzheimer's disease and glaucoma. Another patent also emphasizes a compound that serves a similar purpose, reinforcing his commitment to addressing neurodegenerative conditions.

Career Highlights

Throughout his career, Kiyohiro Samizu has worked with notable companies such as Astellas Pharma GmbH and Comentis, Inc. His work in these organizations has allowed him to advance his research and contribute to innovative pharmaceutical solutions.

Collaborations

Samizu has collaborated with esteemed colleagues, including Ryosuke Munakata and Noriyuki Kawano. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical inventions.

Conclusion

Kiyohiro Samizu's contributions to pharmaceutical chemistry, particularly through his innovative patents, highlight his role as a key inventor in the field. His work continues to pave the way for advancements in treatments for serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…